# Veradermics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/veradermics

- Industry: Biotechnology
- Headquarters: New Haven, US
- Website: www.veradermics.com/
- Total disclosed funding: $224M
- Latest round: Series C (Oct 14, 2025)
- Investors on record: 16

## About

Based in Connecticut, US, and founded in 2019, Veradermics, Inc. is a medical dermatology company developing therapeutics. In February 2026, Veradermics, Inc. raised USD 256.32 million in an IPO, selling 150.78 million shares at USD 17 per share, above the USD 14-16 range, on the New York Stock Exchange (NYSE) under the ticker symbol "MANE," valuing the company at approximately USD 596 million. Veradermics focuses on developing skincare treatments, using the expertise of its board-certified dermatologists. The FIRM main product, VDPHL, is a non-hormonal oral treatment taken once a day to treat androgenetic alopecia, or pattern hair loss. The company is also working on four other treatments for common skin conditions, including warts, alopecia areata, molluscum contagiosum, and eczema, for both adults and children. Veradermics primarily sells its products in North America and Europe, aiming to provide solutions for common skin problems. Veradermics generates revenue through venture-backed funding rounds and aims for future income via commercialization of VDPHL01, an oral hair regrowth therapeutic in Phase 3 trials. The company will use the February 2026 funding to advance the clinical development, regulatory approval and commercialization of its hair loss therapy and for general corporate purposes.

## Funding rounds

- Series C, Oct 14, 2025, $135M — SR One, Columbia Threadneedle Investments, Marshall Wace, Viking Global Investors, Longitude Capital, Surveyor Capital, Invus Financial Advisors, LifeSci Partners, Suvretta Capital Management, Infinitium
- Series B, Nov 25, 2024, $67M — Prospect Hill Growth Partners, OUP (Osage University Partners), Connecticut Innovations, Longitude Capital, Surveyor Capital, PhiFund Ventures, Suvretta Capital Management, Vladimir Coric Family Trust
- Series A, Sep 22, 2021, $22M — Prospect Hill Growth Partners, Connecticut Innovations, Werth Family Investment Associates, Vladimir Coric Family Trust

## Investors

- Prospect Hill Growth Partners (https://capitalatlas.ai/funds/prospect-hill-growth-partners) — Series A, Series B
- Connecticut Innovations (https://capitalatlas.ai/funds/connecticut-innovations) — Series A, Series B
- Werth Family Investment Associates (https://capitalatlas.ai/funds/werth-family-investment-associates) — Series A
- Vladimir Coric Family Trust — Series A, Series B
- OUP (Osage University Partners) (https://capitalatlas.ai/funds/oup-osage-university-partners) — Series B
- Longitude Capital (https://capitalatlas.ai/funds/longitude-capital) — Series B, Series C
- Surveyor Capital — Series B, Series C
- PhiFund Ventures (https://capitalatlas.ai/funds/phifund-ventures) — Series B
- Suvretta Capital Management — Series B, Series C
- SR One (https://capitalatlas.ai/funds/sr-one) — Series C
- Columbia Threadneedle Investments — Series C
- Marshall Wace (https://capitalatlas.ai/funds/marshall-wace) — Series C
- Viking Global Investors (https://capitalatlas.ai/funds/viking-global-investors) — Series C
- Invus Financial Advisors (https://capitalatlas.ai/funds/invus-financial-advisors) — Series C
- LifeSci Partners (https://capitalatlas.ai/funds/lifesci-partners) — Series C
- Infinitium — Series C